ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

JMT203

A development code. Also written as “JMT203 Injection”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by CSPC Pharmaceutical Group.

Furthest: phase 2, since Feb 18, 20251 company-led study, 1 open or runningNext primary completion: Aug 14, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group11 open or runningphase 2since Feb 18, 2025Feb 18, 2025Aug 14, 2027phase 2 · NCT06868849

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 18, 2025First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06868849 · 307 planned · China

Ahead

  1. Aug 14, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06868849

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06868849Carcinoma, Non-Small-Cell Lung · China2RecruitingAug 14, 2027307

How it is read

Names in the registry

  • “JMT203 Injection”, 2 entries

Codes read as this program: JMT203.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.